Chad Therapeutics (CTU) 10-Q 2006 Q3 Quarterly report

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION
906 OF SARBANES OXLEY ACT OF 202

Earl L Yager, as Chief Executive Officer of CHAD Therapeutics, Inc. (the “Company”), and Tracy A. Kern, as Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. §1350, that:

     (1) the Company’s Quarterly Report of Form 10-Q for the quarterly period ended December 31, 2005, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

     (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 14, 2006	/s/ Earl L Yager
	Earl L. Yager
	Chief Executive Officer Of CHAD Therapeutics, Inc.
Dated: February 14, 2006	/s/ Tracy A. Kern
	Tracy A. Kern
	Chief Financial Officer Of CHAD Therapeutics, Inc.